An analysis of the impact of annual cancer genetic testing guideline updates on a past patient population
Journal of Genetic Counseling · 2024
DOI: 10.1002/jgc4.1822 ↗Kurz gefasst
Leitlinie in der Zeitschrift Journal of Genetic Counseling, 2024. Verfasst von Jordan Johnson und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Genetics and Genome Sciences, Case Western Reserve University School of Medicine, Cleveland, Ohio, USA. Hauptthemen laut MEDLINE: Genetic Testing. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 23 Literaturangaben. Gefördert von: Case Western Reserve University.
Abstract (Originalsprache)
Germline genetic testing for cancer predisposition genes has become an essential component of cancer treatment and risk reduction. The National Comprehensive Cancer Network (NCCN) releases annual genetic testing guidelines that identify characteristics of patients that could be affected by a hereditary cancer syndrome. These guidelines have broadened over time and the implications for past patients of cancer genetics clinics are not well understood. This study is a retrospective chart review aimed at determining the percentage and characteristics of past patients that meet updated NCCN guidelines (Breast, Ovarian, and Pancreas [BOP] v1.2022 and Colorectal [CRC] v1.2021), patients that attended a follow‐up appointment, and patients who went on to receive genetic testing. Clinical data and characteristics were compared between the study population as a whole and the cohort of patients that met updated NCCN guidelines BOP v1.2022 and CRC v1.2021. The study population consisted of 280 patients with 76 (27.1%) patients meeting updated NCCN guidelines BOP v1.2022 and CRC v1.2021. The year of initial cancer genetic counseling appointment was statistically significant ( p = 0.023) with patients more likely to meet NCCN guidelines BOP v1.2022 and CRC v1.2021 with earlier initial cancer genetic counseling appointments. In the cohort that met updated NCCN guidelines BOP v1.2022 and CRC v1.2021, the most common reason was a change in the NCCN guidelines (BOP or CRC) (54/76, 71.1%) with triple‐negative breast cancer diagnosed at any age being the most impactful guideline change (19/54, 35.2%). Twenty‐one patients attended a follow‐up appointment (7.5%) and of those that received genetic testing (17/21, 81%) most received negative results (13/17, 61.9%), with one pathogenic, low penetrance result (1/17, 5.9%, CHEK2 p.I157T). Provider‐initiated follow‐up was attributed to most follow‐up appointments (16/21, 76.2%) implying patients do not tend to follow‐up on their own. Education to non‐genetics providers as well as targeted implementation of follow‐up protocols possibly managed by genetic counseling assistants and utilizing electronic medical record (EMR) patient messaging could lead to improved patient follow‐up.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Genetics and Genome Sciences, Case Western Reserve University School of Medicine, Cleveland, Ohio, USA.
- Department of Genetics and Genomics, The MetroHealth System, Cleveland, Ohio, USA.
- Center for Personalized Genetic Healthcare, Cleveland Clinic Foundation, Cleveland, Ohio, USA.
ORCID-Profile: Jordan Johnson
Förderung
- Case Western Reserve University
Zitieren
APA
Johnson, J., Hogan, E., Merrill, M., & Noss, R. (2024). An analysis of the impact of annual cancer genetic testing guideline updates on a past patient population. Journal of Genetic Counseling. https://doi.org/10.1002/jgc4.1822
Vancouver
Johnson J, Hogan E, Merrill M, Noss R. An analysis of the impact of annual cancer genetic testing guideline updates on a past patient population. Journal of Genetic Counseling. 2024. doi:10.1002/jgc4.1822
BibTeX
@article{Johnson2024,
author = {Johnson, Jordan and Hogan, Elizabeth and Merrill, Michelle and Noss, Ryan},
title = {An analysis of the impact of annual cancer genetic testing guideline updates on a past patient population},
journal = {Journal of Genetic Counseling},
year = {2024},
doi = {10.1002/jgc4.1822}
}
EUVIMED